Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-KPD-AutoHSCT Scheme for MM with Renal Injury
NCT06203145Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jan 2024
- Primary completion
- Nov 2025
- Modality
- Reversible Covalent Inhibitors, Irreversible Covalent Inhibitors, Molecular Glues
- Countries
- 1
01
Overview
Open-label, single-arm trial of carfilzomib and pomalidomide in multiple myeloma (MM) and renal impairment (RI), sponsored by Peking University First Hospital. Primary endpoint: Renal Response Rates at 2 years. Started Jan 2024; status: recruiting.
02
Drugs
carfilzomibpomalidomide
03
Conditions
multiple myeloma (MM)renal impairment (RI)
Beyond the preview
Go deeper on NCT06203145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06203145.